Mass Spec Studio for Clinical Proteomics

There are two phases to the development of a biomarker: discovery and validation. In discovery, an emerging best-in-class solution uses an untargeted mass spec method called “Data Independent Acquisition” (DIA) that generates large, overlapping sets of signals. These signals must be mined for protein identity and abundance. After discovery, the activity shifts towards validation often using a more targeted mass spec method, called “Parallel Reaction Monitoring” (PRM). Easy-to-use but powerful software tools are required to accelerate clinical biomarker discovery.